Search published articles


Showing 3 results for Fluconazole
Comparison Between the Effect of Fluconazole and Oral Protexin Combination and Fluconazole on the Treatment of Vulvovaginal Candidiasis
Soheila Nouraei, Sedigheh Amir Ali Akbari, Masomeh Jorjani, Hamid Alavi Majd, Ayyob Ghaforian,
Volume 16, Issue 4 (7-2013)
Abstract

Background: Genital tract infections are one of the main causes of frequent referrals to gynecological clinics. Vulvovaginal candidiasis is the second common infectious vaginitis. On the other hand, probiotics are microorganisms that can have beneficial effects on the host. Noticing the limited number of studies reporting new treatments for this disease, the present study was designed to compare the effects of the combination of fluconazole and oral protexin and fluconazole on the treatment of vulvovaginal candidiasis.

Materials and Methods: A double-blind clinical trial was conducted on 90 women who were referred to the 12-e-Bahman Clinic in 2011. The patients were randomly classified into "combination of fluconazole and oral protexin" or "fluconazole and placebo" groups. Data were analyzed by descriptive statistics and inferential statistics (t-test, Chi-square test, Fisher’s exact test, and McNemar’s test).

Results: The combinations, fluconazole-oral protexin and fluconazole-placebo, were equally effective in reduction of complaints and symptoms however, the effect of fluconazole-oral protexin on dysuria was more (p=0.02). Also, the fluconazole-oral protexin combination elicited a better therapeutic response (p=0.01). In addition, fluconazole-oral protexin combination treatment demonstrated a better recovery time (p=0.04).

Conclusion: This study demonstrated that complementary treatment with probiotic lactobacillus increased the efficacy of fluconazole in treatment of vulvovaginal candidiasis. Further research, however, is suggested.


Correlation between ERG11 gene mutations and fluconazole resistance in Candida albicans strains isolates isolated in from Rasht in 2015-2016 years
Saeedeh Balabandi, Zeinab Khazaei -Koohpar, Najmeh Ranji,
Volume 20, Issue 7 (10-2017)
Abstract
Abstract
Background: Candida albicans as an opportunistic fungal pathogen in human causes candidiasis. The widespread use of azoles has led to the increase of azole resistance in Candida albicans isolates. Mutation in the ERG11 gene is one of several azole resistance reasons in Candida albicans. The aim of this study was to find ERG11 gene mutations in fluconazole resistant isolates in Rasht.
Materials and methods: Candida albicans isolates were identified by standard identification methods such as germ tubes. The fluconazole resistance and susceptibility of the isolates was evaluated by Disc diffusion and MIC methods. For mutation determining, ERG11 gene was amplified by PCR and then sequenced in clinical isolates.
Results: From 23 isolates of Candida albicans, 20 isolates were fluconazole resistant. The MIC of fluconazole in these isolates was determined between 128 to 2048µg/ml. Also, sequencing analysis showed that 10 fluconazole resistant isolates had two missense mutations (D116E and E266D) in ERG11 gene.
Conclusion: In this study, resistance to high concentration of fluconazole shows that different mechanisms simultaneously implicated in developing azoles resistance in the isolates. Association of ERG11 gene mutation and deregulation of other genes can be led to resistance to high fluconazole concentration in this study.
 

Antibiofilm Activity of Fluconazole/Terbinafine Combination in Candida albicans HWP1 Gene Expression
Alireza Khodavandi, Fahimeh Alizadeh, Nedasadat Marashi,
Volume 20, Issue 11 (2-2018)
Abstract
Abstract
Background: Biofilm formation represents one of the major virulence factors of Candida albican. However, the number of antifungal drugs is limited for the treatment of candidiasis. Combination therapy is one of the most frequently used techniques to alleviate this problem. In this study, we aimed to evaluate the antifungal activity of fluconazole and terbinafine alone and in combination on C. albicans biofilm inhibition.
Materials and Methods: In this cross- sectional study, 10 clinical isolates of C. albicans were identified from the immunocompromised patients. Antifungal susceptibilities were performed using the CLSI standard reference method. The crystal violet colorimetric method, direct microscopic observation and expression of HWP1 gene at different concentrations based on MICs were carried out to investigate inhibition of biofilm formation in C. albicans treated alone and in combination with fluconazole and terbinafine.
Results: The data indicated that combination of fluconazole with terbinafine exerted synergistic effects with fractional inhibitory concentration index ranged from 0.375 to 1.5. The combination of fluconazole with terbinafine reduced the number of yeast form and inhibited the biofilm formation. Finally, the expression level of HWP1 was down regulated (p< 0.05).
Conclusion: These results suggest the possibility of fluconazole/ terbinafine to treat candidiasis with a higher efficiency. In addition, HWP1 gene could be probable target in synergistic interaction of fluconazole/ terbinafine against C. albicans biofilm.
 

Page 1 from 1     

© 2025 CC BY-NC 4.0 | Journal of Arak University of Medical Sciences

Designed & Developed by : Yektaweb